{"id":61131,"date":"2026-03-24T19:25:51","date_gmt":"2026-03-24T11:25:51","guid":{"rendered":"https:\/\/flcube.com\/?p=61131"},"modified":"2026-03-24T19:25:52","modified_gmt":"2026-03-24T11:25:52","slug":"hanmi-pharmaceutical-partners-with-chongqing-zhongfu-amlodipine-losartan-fixed-dose-combo-targets-china-out-of-hospital-digital-market","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=61131","title":{"rendered":"Hanmi Pharmaceutical Partners with Chongqing Zhongfu \u2013 Amlodipine\/Losartan Fixed-Dose Combo Targets China Out-of-Hospital Digital Market"},"content":{"rendered":"\n

Hanmi Pharmaceutical<\/strong> (South Korea) announced a partnership<\/strong> with Chongqing Zhongfu Pharmaceutical Co., Ltd.<\/strong> to jointly promote amlodipine\/losartan<\/strong> in China’s out-of-hospital market via internet channels<\/strong>. The collaboration expands access to the fixed-dose combination antihypertensive<\/strong>, originally co-developed with Merck<\/strong> and marketed as Amosartan (South Korea, 2009)<\/strong> and COZAAR XQ (international)<\/strong>, leveraging digital platforms to drive disease awareness and patient adherence<\/strong> among China’s 200+ million hypertensive population<\/strong>.<\/p>\n\n\n\n

Partnership Framework<\/h2>\n\n\n\n
Element<\/th>Detail<\/th><\/tr><\/thead>
Parties<\/strong><\/td>Hanmi Pharmaceutical (South Korea) + Chongqing Zhongfu Pharmaceutical Co., Ltd. (China)<\/td><\/tr>
Product<\/strong><\/td>Amlodipine\/losartan fixed-dose combination<\/td><\/tr>
Brand Names<\/strong><\/td>Amosartan<\/strong> (South Korea); COZAAR XQ<\/strong> (Merck international); China generic positioning<\/td><\/tr>
Channel Focus<\/strong><\/td>Out-of-hospital market via Internet<\/strong> (e-commerce, digital health platforms)<\/td><\/tr>
Strategic Goal<\/strong><\/td>Expand accessibility + promote hypertensive disease awareness<\/td><\/tr>
Launch History<\/strong><\/td>South Korea 2009<\/strong>; China approval January 2022<\/strong> (Beijing Hanmi promotion); 60+ countries<\/strong> globally<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Product Profile & Market Position<\/h2>\n\n\n\n
Attribute<\/th>Amlodipine\/Losartan Specification<\/th><\/tr><\/thead>
Mechanism<\/strong><\/td>Dual-action:<\/strong> calcium channel blockade (amlodipine) + angiotensin II receptor blockade (losartan)<\/td><\/tr>
Clinical Benefit<\/strong><\/td>Synergistic BP reduction<\/strong>; improved adherence vs. dual-pill regimens; reduced edema vs. amlodipine monotherapy<\/td><\/tr>
Target Population<\/strong><\/td>Hypertensive patients requiring dual therapy<\/strong>; preference for single-pill convenience<\/strong><\/td><\/tr>
Global Reach<\/strong><\/td>60+ countries<\/strong> with Merck international promotion<\/td><\/tr>
China Status<\/strong><\/td>Approved January 2022<\/strong>; previously hospital-focused; now expanding to digital\/outpatient channels<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Rationale & Digital Strategy<\/h2>\n\n\n\n
Hanmi\/Zhongfu Collaboration<\/th>Implementation<\/th><\/tr><\/thead>
Out-of-Hospital Access<\/strong><\/td>E-commerce platforms (JD Health, Alibaba Health) for prescription fulfillment and adherence programs<\/td><\/tr>
Disease Awareness<\/strong><\/td>Digital campaigns targeting undiagnosed\/untreated hypertensives; telemedicine integration for remote monitoring<\/td><\/tr>
Adherence Improvement<\/strong><\/td>Subscription models, automated refill reminders, BP tracking app integration<\/td><\/tr>
Market Expansion<\/strong><\/td>Captures primary care and self-pay segments<\/strong> beyond hospital formulary constraints<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Context & Competitive Dynamics<\/h2>\n\n\n\n
Factor<\/th>Implication<\/th><\/tr><\/thead>
China Hypertension Burden<\/strong><\/td>~270 million adults<\/strong> affected; <20% controlled<\/strong>; massive unmet need for accessible, affordable dual therapy<\/td><\/tr>
Fixed-Dose Combination Trend<\/strong><\/td>FDCs improve adherence 20\u201330% vs. free combinations; preferred by guidelines but limited reimbursement in China<\/td><\/tr>
Digital Pharma Growth<\/strong><\/td>RMB 50+ billion<\/strong> annual online prescription drug sales; cardiovascular category expanding rapidly post-COVID<\/td><\/tr>
Competitive Landscape<\/strong><\/td>Generic amlodipine\/losartan FDCs (local Chinese pharma); Hanmi\/Zhongfu differentiation via brand recognition + digital engagement<\/strong><\/td><\/tr>
Pricing Strategy<\/strong><\/td>Expected RMB 2\u20134 daily therapy cost<\/strong> \u2013 competitive with generics but premium for convenience\/adherence support<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n